TY - JOUR
T1 - Integrated Genome and Protein Editing Swaps α-2,6 Sialylation for α-2,3 Sialic Acid on Recombinant Antibodies from CHO
AU - Chung, Cheng Yu
AU - Wang, Qiong
AU - Yang, Shuang
AU - Yin, Bojiao
AU - Zhang, Hui
AU - Betenbaugh, Michael
N1 - Publisher Copyright:
Copyright © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Immunoglobin G with α-2,6 sialylation has been reported to have an impact on antibody-dependent cellular cytotoxicity and anti-inflammatory efficacy. However, production of antibodies with α-2,6 sialylation from Chinese hamster ovary cells is challenging due to the inaccessibility of sialyltransferases for the heavy chain N-glycan site and the presence of exclusively α-2,3 sialyltransferases. In this study, combining mutations on the Fc regions to allow sialyltransferase accessibility with overexpression of α-2,6 sialyltransferase produced IgG with significant levels of both α-2,6 and α-2,3 sialylation. Therefore, ST3GAL4 and ST3GAL6 genes were disrupted by CRISPR/Cas9 to minimize the α-2,3 sialylation. Sialidase treatment and SNA lectin blot indicated greatly increased α-2,6 sialylation level relative to α-2,3 sialylation for the α-2,3 sialyltransferase knockouts when combined with α-2,6 sialyltransferase overexpression. Indeed, α-2,3 linked sialic acids were not detected on IgG produced from the α-2,3 sialyltransferase knockout-α-2,6 sialyltransferase overexpression pools. Finally, glycoprofiling of IgG with four amino acid substitutions expressed from an α-2,3 sialyltransferase knockout-α-2,6 sialyltransferase stable clone resulted in more than 77% sialylated glycans and more than 62% biantennary disialylated glycans as indicated by both MALDI-TOF and LC-ESI-MS. Engineered antibodies from these modified Chinese hamster ovary cell lines will provide biotechnologists with IgGs containing N-glycans with different structural variations for examining the role of glycosylation on protein performance.
AB - Immunoglobin G with α-2,6 sialylation has been reported to have an impact on antibody-dependent cellular cytotoxicity and anti-inflammatory efficacy. However, production of antibodies with α-2,6 sialylation from Chinese hamster ovary cells is challenging due to the inaccessibility of sialyltransferases for the heavy chain N-glycan site and the presence of exclusively α-2,3 sialyltransferases. In this study, combining mutations on the Fc regions to allow sialyltransferase accessibility with overexpression of α-2,6 sialyltransferase produced IgG with significant levels of both α-2,6 and α-2,3 sialylation. Therefore, ST3GAL4 and ST3GAL6 genes were disrupted by CRISPR/Cas9 to minimize the α-2,3 sialylation. Sialidase treatment and SNA lectin blot indicated greatly increased α-2,6 sialylation level relative to α-2,3 sialylation for the α-2,3 sialyltransferase knockouts when combined with α-2,6 sialyltransferase overexpression. Indeed, α-2,3 linked sialic acids were not detected on IgG produced from the α-2,3 sialyltransferase knockout-α-2,6 sialyltransferase overexpression pools. Finally, glycoprofiling of IgG with four amino acid substitutions expressed from an α-2,3 sialyltransferase knockout-α-2,6 sialyltransferase stable clone resulted in more than 77% sialylated glycans and more than 62% biantennary disialylated glycans as indicated by both MALDI-TOF and LC-ESI-MS. Engineered antibodies from these modified Chinese hamster ovary cell lines will provide biotechnologists with IgGs containing N-glycans with different structural variations for examining the role of glycosylation on protein performance.
KW - CHO cells
KW - Glycoengineering
KW - Monoclonal Antibody
KW - α -2,6 Sialylation
KW - α-2,3 Sialylation
UR - http://www.scopus.com/inward/record.url?scp=85010644597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010644597&partnerID=8YFLogxK
U2 - 10.1002/biot.201600502
DO - 10.1002/biot.201600502
M3 - Article
C2 - 27943633
AN - SCOPUS:85010644597
SN - 1860-6768
VL - 12
JO - Biotechnology Journal
JF - Biotechnology Journal
IS - 2
M1 - 1600502
ER -